
- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
When blood clots break down too quickly, aminocaproic acid is used to control bleeding.
This kind of bleeding can happen before, during, or after surgery on the heart or liver; in individuals with particular bleeding disorders; in individuals who have cancer of the cervix (the opening of the uterus), lung, prostate, or stomach; and in pregnant women who are experiencing placental abruption, in which the baby's placenta separates from the uterus before it is ready to be born.
Aminocaproic acid is also used to stop bleeding in the urinary tractâthe organs in the body that make and excrete urineâthat can happen after surgery on the prostate or kidneys or in people who have certain kinds of cancer.
Before you begin treatment, your doctor may order tests to determine the cause of your bleeding. Aminocaproic acid should not be used to treat bleeding that is not caused by faster than normal clot breakdown.
Aminocaproic acid belongs to the hemostatics class of drugs.By slowing the breakdown of blood clots, it works.
Aminocaproic acid can be taken orally as a solution (liquid) or as a tablet. Typically, it is taken once per hour for about eight hours or until the bleeding stops.
When aminocaproic corrosive is utilized to treat progressing dying, it is normally taken each 3 to 6 hours.
The Global Aminocaproic Acid market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Aminocaproic Acid Tablets Have Been Approved and Are Now Available from ANI Pharmaceuticals.
Aminocaproic Acid Tablets USP, 500mg was approved by the U.S. Food and Drug Administration (FDA) and introduced by ANI Pharmaceuticals, Inc.
"This is the seventh generic product launch by ANI, and it reaffirms the commitment to accelerate product introductions to the market.
One of the generic products in the pipeline that they acquired earlier this year from Amerigen Pharmaceuticals, Ltd. is this important treatment.
Aminocaproic Acid Tablets can help improve hemostasis in cases where fibrinolysis is to blame for the bleeding.
Transfusion of appropriate blood products and other emergency measures may be required in life-threatening circumstances.
Please refer to the Full Prescribing Information for additional details, including the complete list of indications and applications.
An integrated specialty pharmaceutical company, ANI Pharmaceuticals, Inc. creates, manufactures, and markets prescription medications under brand names and generics.
Drugs, oncolytics (anti-cancer drugs), hormones and steroids, and complex formulations involving extended-release and combination products are currently the company's targeted areas for product development.
Sl no | Topic |
1 | Market Segmentation |
2 | Scope of the report |
3 | Abbreviations |
4 | Research Methodology |
5 | Executive Summary |
6 | Introduction |
7 | Insights from Industry stakeholders |
8 | Cost breakdown of Product by sub-components and average profit margin |
9 | Disruptive innovation in the Industry |
10 | Technology trends in the Industry |
11 | Consumer trends in the industry |
12 | Recent Production Milestones |
13 | Component Manufacturing in US, EU and China |
14 | COVID-19 impact on overall market |
15 | COVID-19 impact on Production of components |
16 | COVID-19 impact on Point of sale |
17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
21 | Product installation rate by OEM, 2023 |
22 | Incline/Decline in Average B-2-B selling price in past 5 years |
23 | Competition from substitute products |
24 | Gross margin and average profitability of suppliers |
25 | New product development in past 12 months |
26 | M&A in past 12 months |
27 | Growth strategy of leading players |
28 | Market share of vendors, 2023 |
29 | Company Profiles |
30 | Unmet needs and opportunity for new suppliers |
31 | Conclusion |
32 | Appendix |